Aldo P Maggioni Selected Research

Vasopressins (Vasopressin)

1/2018	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial).
4/2016	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure.
2/2016	Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).
1/2016	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
10/2015	Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial.
12/2014	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
9/2014	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).
12/2013	Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
12/2013	Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial).
12/2013	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aldo P Maggioni Research Topics

Disease

187	Heart Failure 06/2022 - 01/2002
54	Myocardial Infarction 12/2022 - 10/2002
39	Atrial Fibrillation 11/2022 - 07/2004
38	Stroke (Strokes) 12/2022 - 03/2004
25	Acute Coronary Syndrome 01/2022 - 10/2002
24	Coronary Artery Disease (Coronary Atherosclerosis) 12/2022 - 05/2009
24	Type 2 Diabetes Mellitus (MODY) 01/2022 - 09/2010
23	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 08/2004
22	Hypertension (High Blood Pressure) 10/2021 - 01/2002
20	Hemorrhage 11/2022 - 02/2009
17	Diabetes Mellitus 01/2021 - 02/2010
15	Left Ventricular Dysfunction 01/2021 - 08/2003
14	Peripheral Arterial Disease 12/2022 - 06/2014
14	Chronic Obstructive Pulmonary Disease (COPD) 11/2022 - 09/2007
12	Hypotension (Low Blood Pressure) 11/2019 - 11/2003
11	ST Elevation Myocardial Infarction 06/2022 - 04/2003
10	Cardiomyopathies (Cardiomyopathy) 01/2022 - 03/2007
10	Heart Diseases (Heart Disease) 01/2022 - 03/2002
9	Chronic Renal Insufficiency 10/2021 - 12/2012
9	Infarction (Infarctions) 10/2020 - 12/2006
9	Body Weight (Weight, Body) 01/2017 - 03/2007
6	Inflammation (Inflammations) 01/2021 - 07/2011
6	Dyspnea (Shortness of Breath) 10/2019 - 03/2007
6	Anemia 01/2017 - 03/2005
5	Neoplasms (Cancer) 01/2021 - 07/2012
5	Heart Valve Diseases (Valvular Heart Disease) 01/2021 - 05/2012
5	Unstable Angina 01/2018 - 10/2002
5	Sudden Death 01/2017 - 10/2002
4	Mitral Valve Insufficiency (Mitral Regurgitation) 01/2022 - 05/2013
4	Coronary Disease (Coronary Heart Disease) 10/2021 - 01/2018
4	Myocardial Ischemia (Ischemic Heart Diseases) 01/2021 - 07/2004
4	Cardiac Arrhythmias (Arrythmia) 01/2021 - 01/2014
4	Ischemic Stroke 10/2020 - 06/2013
4	Vascular Diseases (Vascular Disease) 10/2020 - 05/2010
4	Hyperkalemia 11/2019 - 03/2013
4	Edema (Dropsy) 10/2019 - 03/2007
4	Systolic Heart Failure 09/2014 - 06/2007
3	Cardiogenic Shock 06/2022 - 10/2008
3	Weight Loss (Weight Reduction) 01/2022 - 09/2010
3	Insulin Resistance 01/2022 - 06/2011
3	Ischemia 10/2021 - 01/2019
3	Heart Arrest (Cardiac Arrest) 01/2021 - 09/2010
3	Non-ST Elevated Myocardial Infarction 01/2021 - 09/2003

Drug/Important Bio-Agent (IBA)

37	Valsartan (Vals)FDA Link 11/2021 - 10/2002
32	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2021 - 03/2002
27	Vasopressins (Vasopressin)IBA 01/2018 - 03/2007
27	Tolvaptan FDA Link 01/2018 - 03/2007
20	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 08/2002
18	Natriuretic PeptidesIBA 01/2022 - 07/2004
17	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2022 - 02/2009
17	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2004
17	Angiotensin Receptor AntagonistsIBA 12/2021 - 01/2002
14	CreatinineIBA 11/2022 - 10/2006
14	AnticoagulantsIBA 02/2022 - 09/2009
14	DiureticsIBA 01/2021 - 06/2003
13	RivaroxabanIBA 12/2022 - 01/2017
13	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 08/2002
13	aliskiren FDA Link 01/2018 - 05/2008
11	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022 - 01/2017
10	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 02/2007
10	Mineralocorticoid Receptor AntagonistsIBA 01/2021 - 07/2011
9	Hemoglobins (Hemoglobin)IBA 10/2018 - 03/2005
9	Pharmaceutical PreparationsIBA 01/2017 - 07/2004
8	Angiotensin Receptors (Angiotensin II Receptor)IBA 12/2021 - 08/2003
8	Neprilysin (Neutral Endopeptidase)IBA 12/2021 - 01/2017
8	paragonIBA 12/2021 - 01/2017
8	candesartanIBA 01/2018 - 10/2003
8	Renin InhibitorsIBA 01/2018 - 05/2008
7	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2011 - 10/2002
6	omega-Chloroacetophenone (Mace)IBA 01/2022 - 02/2009
6	lixisenatideIBA 01/2022 - 05/2015
6	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2021 - 09/2009
6	Glucose (Dextrose)FDA LinkGeneric 09/2020 - 07/2012
6	ReninIBA 01/2018 - 09/2005
5	LipidsIBA 01/2021 - 10/2002
5	Exenatide (Byetta)FDA Link 01/2020 - 04/2016
5	SodiumIBA 04/2016 - 03/2007
4	CholesterolIBA 12/2022 - 10/2002
4	Insulin (Novolin)FDA Link 10/2021 - 01/2015
4	Colchicine FDA LinkGeneric 01/2021 - 12/2019
4	Uric Acid (Urate)IBA 01/2021 - 12/2014
4	vericiguatIBA 01/2020 - 12/2015
4	Darbepoetin alfa (Aranesp)FDA Link 01/2018 - 08/2009
4	sibutramine (Meridia)FDA Link 03/2017 - 11/2008
4	Captopril (Capoten)FDA LinkGeneric 06/2016 - 08/2003
4	Rosuvastatin Calcium (Crestor)FDA Link 12/2015 - 10/2008
4	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 11/2013 - 10/2008
4	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 02/2013 - 10/2008
4	AldosteroneIBA 04/2012 - 09/2005
4	Neurotransmitter Agents (Neurotransmitter)IBA 09/2005 - 11/2002
3	Troponin T (Troponin T1)IBA 01/2021 - 09/2007

Therapy/Procedure

73	Therapeutics 06/2022 - 09/2003
12	Patient Readmission 01/2022 - 05/2005
12	Percutaneous Coronary Intervention 01/2022 - 12/2006
8	Secondary Prevention 01/2021 - 03/2006
8	Length of Stay 01/2020 - 04/2003
6	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2021 - 09/2009
6	Electric Countershock (Cardioversion) 01/2018 - 03/2004
4	Catheter Ablation 01/2022 - 06/2014
4	Defibrillators (Defibrillator) 10/2020 - 12/2012